HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 52, 50710-50715, December 27, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/52/50710    most recent M208826200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joo, N. S. Articles by Wine, J. J. Search for Related Content PubMed PubMed Citation Articles by Joo, N. S. Articles by Wine, J. J. Social Bookmarking                      What's this?

Absent Secretion to Vasoactive Intestinal Peptide in Cystic Fibrosis Airway Glands^*

Nam Soo Joo, Toshiya Irokawa, Jin V. Wu, Robert C. Robbins^§, Richard I. Whyte^§, and Jeffrey J. Wine^¶

From the  Cystic Fibrosis Research Laboratory, Stanford University, Stanford, California 94305-2130 and the ^§ Cardiothoracic Surgery and School of Medicine, Stanford University, Stanford, California 94305-5407

Received for publication, August 29, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

We are testing the hypothesis that the malfunctioning of airway gland serous cells is a component of cystic fibrosis (CF) airway disease. CF is caused by mutations that disrupt CF transmembrane conductance regulator, an anion channel essential for proper fluid secretion in some epithelia. Submucosal glands supply most of the mucus in upper airways, and gland serous cells are the primary site of CF transmembrane conductance regulator expression in airways. We have discovered a major defect in CF glands by in situ optical monitoring of secretions from single human airway glands. CF glands did not secrete to agents that elevated [cAMP]_i (0 responses/450 glands, 8 subjects), whereas glands were responsive in all donor tracheas (605/827 glands, 15 subjects) and in bronchi from subjects who were transplanted because of other lung diseases (148/166 glands, n = 10). CF glands secreted to cholinergic stimulation, and serous cells were abundant in glands from all CF subjects. The complete absence of secretion to agents that elevate [cAMP]_i suggests that altered secretion of gland mucus could contribute to CF lung disease.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Cystic fibrosis is characterized by widespread dysfunction of exocrine organs (1). Organs that secrete mucus or macromolecules, including the sinuses, vas deferens, pancreas, and intestine, become partially or completely filled with inspissated secretions, often before or shortly after birth, leading in some cases to complete blockage and degeneration (2-4). Inadequate hydration of epithelial fluids underlies much of this pathology. The proposed role of salt and water was made even before the discovery that CF¹ is caused by mutations in CFTR, an anion channel and channel regulator essential for proper salt and water movement across some epithelia (5). There is increasing evidence that this general dysfunction also plays an important role in CF airway disease (6).

The most devastating clinical consequence of CF is chronic infection of airways with normally innocuous bacteria and fungi. There is as yet no consensus on how this is related to altered epithelial salt and water transport, but the earliest and most persistent hypothesis has been that some defect in airway mucus is responsible. The role of mucous clearance as a primary innate defense mechanism of the airways has recently received renewed attention (6). In CF airways, infecting organisms are confined to the mucus (6-9) (for discussion, see Ref. 10), but they are neither killed nor cleared, and their diffusible products provoke an intense but ineffective neutrophilic inflammatory response that further degrades the airways, eventually leading to death from pulmonary failure (11).

Within airways, CFTR is most highly expressed in serous cells of submucosal glands (12). Submucosal glands, which are estimated to supply >95% of upper airway mucus (13), occur with a frequency of ~1/mm² in human trachea (14). Each gland comprises multiple tubules that feed into a collecting duct, which then narrows into a ciliated duct that is continuous with the airway surface (Fig. 1 and Ref. 15). Tubules are lined with mucous cells in their proximal regions and with serous cells in the distal acini (15). Normal glands are ~60% serous and 40% mucous cells by volume, and the abundant serous cells secrete water, electrolytes, and a rich mixture of antimicrobial, anti-inflammatory and antioxidant substances, whereas mucous cells provide most of the mucin component (16, 17). Because of their key role in fighting mucosal infections, serous cells have been described as "immobilized neutrophils" (16).

View larger version (152K): [in this window] [in a new window]   Fig. 1.   Living human submucosal gland. A brightfield image at high contrast of a human submucosal gland following stimulation with carbachol is shown. The gland is viewed through an oil layer, the surface epithelium, and the lamina propria, but all deeper tissue was dissected away. The bubble of mucus secreted by the gland is visible in the oil layer (open arrow). The presumptive collecting duct (C.D.), mucous tubules (M.T.), and serous acini (S.A.) are labeled by reference to the gland reconstruction by Meyrick et al. (15).

Remarkably, despite their possible relevance for CF lung disease, the behavior of intact, CF submucosal glands has never been directly studied. However, ion and fluid secretion is reduced in cultures of CF gland cells (18, 19) and in glands pharmacologically treated with CFTR inhibitors (20). This is consistent with patch clamp studies of primary cultures of serous cells (21) and the Calu-3 serous cell model (22), which indicate that CFTR is the only physiologically relevant apical anion channel in such cells. Ussing chamber studies with permeabilized cell sheets of Calu-3 cells confirm those studies and further indicate that functional CFTR is required for secretion to calcium-elevating agonists (23, 24). Thus, it is predicted that fluid secretion from serous cells in CF glands should be deficient to all mediators. However, because glands also contain mucous cells that do not appear to contain CFTR (12), the expected serous cell defect should be most easily detected if an agonist could be found that preferentially activated serous cell secretion.

Vasoactive intestinal peptide (VIP) stimulates macromolecular secretion from ferret submucosal glands by elevating [cAMP]_i (25, 26) and degranulates ferret gland serous cells (26). In isolated submucosal glands from cats, VIP stimulates glycoconjugate release without stimulating contraction of myoepithelial cells (27). Binding sites for VIP are detected on human submucosal glands (28), and the Calu-3 human serous cell model has functional VPAC₁ (VIP/PACAP-II) receptors (29). In addition to stimulating macromolecular secretion, we recently showed that VIP stimulates sustained fluid secretion from pig submucosal glands (30). Therefore, VIP seemed to be a good choice to test the hypothesis that serous cell secretion is defective in CF glands (24); forskolin was also used to circumvent variations in VIP receptor density (28).

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Airway Preparations-- Human tracheal and bronchial tissues were obtained following lung transplants, or in one CF case, from a necropsy specimen obtained 4 h post-mortem. These studies were approved by the Institutional Review Boards of Stanford University. Usable data were obtained from 33 subjects. Subject characteristics are given in Table I.

Other diseases consisted of patients diagnosed with ₁ antitrypsin deficiency (n = 4), chronic obstructive pulmonary disease (n = 3), and bronchiolitis obliterans pulmonary emphysema, and cardiomyopathy with pulmonary fibrosis plus IgA deficiency (n = 1 each). No obvious differences in gland secretion were observed among the non-CF disease conditions, and so they were grouped for analysis.

Tissues were transported to the laboratory in cold Physiosol^TM solution (Abbott) and were then transferred to ice-cold Krebs-Ringer bicarbonate buffer bubbled with 95% O₂, 5% CO₂, where they were maintained until use. The Krebs-Ringer bicarbonate buffer composition was: 115 mM NaCl, 2.4 mM K₂HPO₄, 0.4 mM KH₂PO₄, 25 mM NaHCO₃, 1.2 mM MgCl₂, 1.2 mM CaCl₂, 10 mM glucose, and 1.0 µM indomethacin. pH was 7.4, and osmolarity was adjusted to ~290 mosM. A piece of ventral trachea or bronchus of ~1.5 cm² was pinned mucosal-side-up, and the mucosa with underlying glands was dissected from the cartilage and mounted in a 35-mm diameter, Sylgard-lined plastic Petri dish with the serosa in the bath (~2 ml volume) and the mucosa in air. The tissue surface was cleaned and blotted dry with cotton swabs and further dried with a stream of gas, after which 30-70 µl of water-saturated mineral oil was placed on the surface. The tissue was warmed to 37 °C at a rate of ~1.5 °C min¹ and continuously superfused with warmed, humidified 95% O₂, 5% CO₂. Pharmacological agents were diluted to final concentration with warmed, gassed bath solution and were added to the serosal side by complete bath replacement.

Two experimental paradigms were used in an attempt to detect minor levels of VIP/forskolin-mediated secretion in CF tissues. In one, we waited until basal secretion (if present) was stopped or stable and then added 1 µM VIP or 10 µM forskolin serially or together. Forskolin was used to control for the possibility that VIP receptors are decreased in CF tissues. After intervals of 40 min to 1 h, 10 µM carbachol was then added to test for gland viability. In the second procedure, we first stimulated transiently with a 2.5 µM solution of carbachol until small bubbles of mucus formed over some gland ducts and then repeatedly replaced the bath with fresh Krebs-Ringer bicarbonate buffer until secretion either stopped or returned to basal values. VIP + forskolin was then applied, and the secreted droplets of mucus were followed for at least 40 min to detect any slight increase in the rate of secretion. A second application of 10 µM carbachol was then applied.

Optical Measurements-- Bubbles of mucus within the oil layer were visualized by oblique illumination, and digital images were captured with a CCD sensor mounted on a microscope (small field) or were obtained directly with the macro lens of a Nikon digital camera (large field). For macro images, each image contained an internal reference grid to compensate for any minor adjustments in magnification made during the experiment. Stored images were analyzed either by direct measurement or with Scion Image software (Scion Corp., Frederick, MD). Mucous volumes were determined from the size of the spherical bubbles; bubbles that were not spherical were omitted from secretion rate analyses. Details of these methods are given in Refs. 30 and 31.

Reagents-- Compounds (Sigma) were made fresh or maintained at 20 °C in the following solvents: carbachol and VIP in distilled water, indomethacin in ethanol, and forskolin in Me₂SO. All were diluted 1:1,000 with bath solution (except indomethacin, which was diluted 1:10,000) immediately before use at the concentrations indicated.

Statistics-- Data are means ± S.E., and Student's t test for unpaired data was used to compare the means of different treatment groups unless otherwise indicated. The difference between the two means was considered to be significant when p < 0.05.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Pieces of human tracheal or bronchial epithelia were prepared so that spherical bubbles of uncontaminated mucus formed within an oil layer on the surface (Fig. 2). The bubbles of mucus, which remained attached to the gland ducts, were optically monitored, and their volumes were estimated by assuming that they were spheres (31). Glands sometimes began secreting at room temperature or started secreting as the bath was warmed (Fig. 2a). This basal secretion was variable, usually diminished or stopped within 30 min after the tissue reached 37 °C, and in general was less pronounced than in sheep and pigs (30, 31).

View larger version (137K): [in this window] [in a new window]   Fig. 2.   Mucus secretion from individual submucosal glands in a donor tracheal epithelium. a and b, two successive images of the same field after 30 min of basal secretion (a) and after 30 min of forskolin-stimulated secretion (b).

Stimulation of Donor Tracheal Glands and Non-CF Bronchial Glands with VIP/Forskolin-- In many glands, including pig bronchial submucosal glands (30, 32), agents that elevate [cAMP]_i produce secretion. In the pancreas and in the Calu-3 serous cell model (33, 34), fluid secretion produced by the elevation of [cAMP]_i is mediated by HCO secretion and is CFTR-dependent. Prior studies of [cAMP]_i-mediated, serous cell protein secretion emphasized pathways through -adrenergic receptors (16), but isoproterenol produces minimal mucous secretion in sheep (31), pigs (30, 32), and humans,² in contrast with VIP (30) and forskolin (32), so these latter agents were used.

Treatment of control tissues with VIP or forskolin resulted in gland mucous secretion that reached a maximal value at about 10 min and was then sustained (Figs. 2b and 3). Secretion in response to VIP or forskolin was observed in each of 15 donor tracheas and in bronchial glands from each of 10 subjects with non-CF diseases (100%).

View larger version (24K): [in this window] [in a new window]   Fig. 3.   Control glands secrete in response to VIP or forskolin. a, responses to VIP and then carbachol of two glands from a donor trachea, monitored with the small field method. b, responses to 1 µM VIP + 10 µM forskolin of 20 glands from a disease control broncheal preparation, monitored with the large field method. Note the long latency of response, variations in response profiles, and 7-8-fold range of volumes secreted.

Secretion Rates-- Secretion rates and profiles in response to VIP/forskolin were quantified for a subset of glands in donors and other diseases (Fig. 3). For a subset of 68 glands from donor tracheas, secretion rates varied from 0 to a maximal rate of 4.50 nl·min¹ gland¹ with a mean rate of 1.04 ± 0.23 nl·min¹ gland¹. In a subset of 48 glands from non-CF diseases, secretion rates ranged from 0 to 5.02 nl·min¹ gland¹ with a mean rate of 1.14 ± 0.35 nl·min¹ gland¹. As with responses to carbachol in sheep (31) and pigs (30), we observed wide variations in secretion rates to VIP/forskolin among glands within subjects (Figs. 2 and 3).

Stimulation of CF Tracheal and Bronchial Glands with VIP/ Forskolin-- In marked contrast with the gland secretory responses seen in all non-CF subjects, submucosal glands from CF subjects were completely refractory to stimulation with VIP or forskolin or to combined treatment (Figs. 4 and 5). We observed no gland secretion to either agent, alone or in combination, in any of eight CF subjects followed for periods of 40-60 min (p < 0.001 for CF versus either control group, Chi square). All of the glands counted as refractory to forskolin were otherwise functional because they secreted in response to the [Ca²⁺]_i-elevating agonist carbachol (Figs. 4 and 5) (35). The percentage of carbachol-responsive glands that also responded to forskolin was 73% for donor trachea (605/827 glands), 89% for bronchi from diseases other than CF (148/166 glands), and 0% for CF (0/450 glands) (Fig. 6).

View larger version (164K): [in this window] [in a new window]   Fig. 4.   CF glands do not secrete to VIP + forskolin. Left column, whole field; right column, an enlargement of the approximate field shown by the box in image a. Bronchial epithelium from a CF subject was transiently stimulated with 2.5 µM carbachol to produce the mucus secretion shown in a. Just after image a, the tissue was stimulated with 1 µM VIP + 10 µM forskolin. Image b, taken 64 min later, shows zero increase in mucus volume during that period. Just after image b, the tissue was again stimulated with 10 µM carbachol, and image c was taken 30 min later. Scale of grid = 0.5 mm.

View larger version (11K): [in this window] [in a new window]   Fig. 5.   Forskolin failed to stimulate mucus secretion from CF glands. Initial secretion was produced by stimulating with 2.5 µM carbachol. After a thorough wash, two glands were followed for 45 min during which a low rate of secretion continued (0.15 nl·min1 gland1). Stimulation for 70 min with 10 µM forskolin caused no increase in the secretion rate, but glands were still viable because they subsequently responded vigorously to 10 µM carbachol.

View larger version (12K): [in this window] [in a new window]   Fig. 6.   Summary of airway submucosal gland responses to VIP/forskolin. a, subjects tested (open bar) and responding (closed bar). b, glands tested (open bar) and responding (closed bar). The asterisk indicates zero responses of all CF glands in all subjects.

Time-dependent Changes in Gland Responsiveness-- In our animal studies of carbachol-mediated secretion, we observed no diminution in responsiveness for tissues up to 24 h after harvest. In human donor tissues, responses to carbachol also appeared to be undiminished for at least 24 h after harvest, but responses to VIP/forskolin were less robust and declined in responsiveness after ~10 h (Fig. 7), although some control glands were observed responding to forskolin for up to 40 h after harvest. The mean ages of tissues at the time of experiments for donors, other diseases, and CF were 15 ± 11, 13 ± 8, and 11 ± 9 h, respectively. Thus, CF tissues were tested on average several hours earlier than controls, eliminating a time-dependent change in responsiveness as a basis for the absence of responses in the CF tissues.

View larger version (11K): [in this window] [in a new window]   Fig. 7.   Time-dependent changes in gland responses to VIP/forskolin. Eleven large format experiments with donor tissues (solid diamonds) and disease controls (open circles) were conducted at varying intervals after harvest. The ordinate shows the percentage of carbachol-responsive glands that also responded to VIP/forskolin. Each point is based on 17-208 responding glands.

Serous Cells Are Abundant in CF Airway Glands-- One possible explanation for the complete lack of cAMP-mediated secretion from CF glands is that such secretion is proposed to originate from serous cells, and conversion of serous to mucous cells has been observed in chronic bronchitis (13, 36). However, such conversion has not been claimed for CF glands, and histological examination of glands from the CF and non-CF subjects we studied showed abundant serous cells in the CF glands (Fig. 8). As reported by others (37-39), simple inspection revealed CF glands to be much larger than glands in the non-CF groups. Although we have not yet quantified the extent of CF gland hypertrophy in our samples, the volume of serous cells in the CF airways we studied is clearly greater than in control tissues, further highlighting the remarkable absence of responsiveness to VIP or forskolin.

View larger version (154K): [in this window] [in a new window]   Fig. 8.   Serous cells are abundant in CF submucosal glands. A 5-µm paraffin section through formalin-fixed bronchial tissue stained with Hematoxylin and Eosin. a (inset), gland at lower magnification, with a portion of the duct opening onto the airway surface at top. Tissue had been stimulated with both forskolin and carbachol. The surface epithelium is missing, and the cartilage, which would normally have occupied the semicircular areas, was micro-dissected away to allow mounting of the flat epithelial sheet required for optimal optical measurements. b, higher magnification of the boxed area of the gland, showing serous (S) and mucous (M) tubules.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

We found that glands from cystic fibrosis airways completely lack secretion stimulated by VIP or forskolin. Our experiments with intact, individually monitored airway glands are the first to demonstrate a defect in CF airway gland volume secretion, but they were preceded by highly informative experiments with primary cultures of serous-like cells derived from CF airway glands, which showed defects in stimulus-evoked short circuit current (18) and fluid secretion (19, 40). Together with localization of CFTR to gland serous cells (12), the present and previous studies establish serous cell dysfunction as a consistent feature of CF submucosal glands.

In our study, serous cell dysfunction was not caused by general debility, inactivity, or inflammation because every non-CF transplant patient responded to VIP/forskolin stimulation. Because forskolin was also ineffective, a deficiency in VIP receptors cannot explain the results, nor can serous-mucous cell conversion because direct inspection revealed abundant serous cells within CF submucosal glands.

The absence of [cAMP]_i-mediated serous cell fluid secretion in CF glands generates a series of questions about gland secretion, which are discussed with reference to the model of gland secretion shown in Fig. 9. In that model, gland mucus is the joint product of serous cells and mucous cells, which normally secrete together. In the following discussion, we distinguish between fluid secretion, which we use as shorthand for electrolyte-driven water transport, and macromolecular secretion, which refers to the secretion of everything else, including mucins and non-mucin proteins. Normal mucus is ~98% water.

View larger version (30K): [in this window] [in a new window]   Fig. 9.   Schematic model of submucosal gland. Four functional compartments have been proposed based on anatomical and immunohistochemical data with CFTR located primarily in serous cells. Pathways that elevate [Ca2+]i, such as ACh, are hypothesized to activate fluid and macromolecular secretion from both serous and mucous cells. Pathways that elevate [cAMP]i, such as VIP, are hypothesized to stimulate serous cells and mucin but not fluid secretion from mucous cells. The CFTR-dependent fluid-secreting pathway is deleted in cystic fibrosis glands.

What Is the Mechanism of Serous Cell Fluid Secretion?-- Our results are consistent with the serous cell model developed by studies of Calu-3 cells (22) and primary cultures of serous cells (18, 19), in which CFTR is required for anion secretion to all mediators (see Introduction). Secretion in response to agents that elevate [Ca²⁺]_i is effected either because CFTR is normally open or because stimulation releases ATP and activates CFTR via an apical autocrine pathway (41).

What Is the Mechanism of Mucous Cell Fluid Secretion?-- Ballard and colleagues (32) showed that mucus secretion by pig airways is maximally stimulated by ACh, that forskolin produces about 60% of that volume, and that the two agonists are not additive. CFTR expression, studied with a well characterized polyclonal antibody and with in situ hybridization, was observed in serous but not mucous tubules (12), although others have reported more extensive expression (42). If CFTR is localized to serous cells, then the absence of forskolin-stimulated secretion in CF glands suggests that normal mucous cells do not secrete fluid in response to forskolin, whereas the continued ability of CF glands to secrete to ACh suggests that fluid secretion by mucous cells does not require CFTR.

How Is Macromolecular Secretion Linked to Fluid Secretion?-- Most prior studies of secretion by cultured gland cells or explants have studied either the release of labeled macromolecules or short circuit current, but these two features of secretion may be uncoupled, especially in glands expressing a genetic defect. Prior studies with explants of whole bronchial segments (43) or primary submucosal gland cell cultures (44) from CF subjects found defective stimulus-evoked secretion of macromolecules. We have not addressed that possibility in the present experiments.

Is Secretion of CF Glands to Cholinergic Agents Normal?-- Given the total loss of secretion to VIP and forskolin in CF glands, is the secretion that remains to carbachol indistinguishable from normal secretion? That is, can this Ca²⁺-elevating agent induce CF serous cells to secrete? The model of gland function shown in Fig. 9 predicts that it cannot, resulting in gland fluid secretion to cholinergic agents that will be mediated only by fluid secretion from mucous cells. It is not a simple matter to determine whether such secretion is deficient. As documented by others, the CF glands in our study appeared much larger than normal, but we have not yet established that point with morphometry. Given the expected hypertrophy of CF submucosal glands (a 4-fold increase was observed in a recent study (39)), a meaningful comparison of secretion rates requires that the rates be expressed relative to gland volumes. Such studies are now underway.

Does the Composition of CF Gland Mucus Differ from Normal?-- Surprisingly, secretions of pig glands in response to forskolin or carbachol had equivalent pH values (30), and again surprisingly, [Na⁺] and pH values for carbachol-stimulated gland secretions were equivalent in CF and control subjects (35). Whether the loss of CFTR will alter protein secretion from serous cells in situ, as occurred for cultured CF gland cells (44), is uncertain. It remains possible that the only component missing from CF mucus is CFTR-dependent salt and water flux.

Does VIP Stimulation of Glands Play an Anti-inflammatory Role?-- VIP is one of the most abundant peptides in the lungs, and a plethora of studies have implicated VIP pathways in the suppression of inflammation and cell damage (45). Exactly how this occurs is unknown. If selective VIP activation of serous cells occurs naturally, it is possible that it could contribute to the anti-inflammatory role of VIP in the airways, and its loss in CF may contribute to the heightened inflammatory state that is a hallmark of CF airway disease (46, 47).

Does the Gland Defect Help Explain the Initiation of Infections in CF Airways?-- People with cystic fibrosis die primarily because their lungs become chronically infected with bacteria and fungi that are easily cleared from normal lungs. Importantly, the pathogens in CF airways are trapped within the mucus (8), but the ability of even normal mucus to inhibit the growth of pathogens is incomplete and wanes over time, emphasizing the importance of mucociliary clearance and cough in limiting the residence time of pathogens in the airways (48). The loss of serous cell secretion may dispose the airways to infections via multiple mechanisms, including slower transport of mucus, absolute stasis of mucus caused by tethering to glands (49), reduced secretion of antimicrobials and anti-inflammatory agents, and reduced bioavailability of these agents because of inadequate dispersal (50). All of these features will be exacerbated by increased fluid absorption and decreased fluid secretion by the surface epithelium (6, 51)

Summary-- Based on the above results and reasoning, our working hypothesis is that secretion by CF submucosal glands lacks the electrolyte-driven fluid component normally supplied by serous cells. Macromolecular secretion by both serous and mucous cells, as well as electrolyte-driven fluid secretion by mucous cells, are hypothesized to be intact. Because the rheological properties of mucous depend critically on the concentration of macromolecules during initial formation of the gel and are resistant to subsequent changes, we hypothesize that a deficiency in electrolyte-driven water transport deep within the gland tubules will increase the concentration of gland mucus, adversely affecting mucus clearance from the glands and contributing to impaired mucociliary and cough clearance.

	ACKNOWLEDGEMENTS

We thank B. A. Reitz, N. R. Henig, J. Theodore, G. J. Berry, and the staff of the Stanford Transplant team for aid in obtaining post-transplant tissue specimens and T. E. Robinson, N. R. Henig, and H. Furthmayr for help in obtaining an autopsy specimen. We are grateful to W. Finkbeiner, M. E. Krouse, P. Quinton, and J. H. Widdicombe for criticisms of an earlier manuscript, to R. Dhillon C. Tseng, and T. Hsu for data analysis, and to M. F. Wine for help in obtaining informed consents. We are especially grateful to the families of organ donors, whose generosity has allowed both life-saving transplants and research into the root causes of lung diseases.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants DK-51817 and HL-60288 and by the Cystic Fibrosis Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ Cystic Fibrosis Research Laboratory, Rm. 450, Bldg. 420, Main Quad, Stanford University, Stanford, CA 94305-2130. Tel.: 650-725-2462; Fax: 650-725-5699; E-mail: wine@stanford.edu.

Published, JBC Papers in Press, October 3, 2002, DOI 10.1074/jbc.M208826200

² N. S. Joo and J. J. Wine, unpublished observations.

	ABBREVIATIONS

The abbreviations used are: CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; VIP, vasoactive intestinal peptide; PACAP, pituitary adenylate cyclase activating peptide.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				B. Illek, Z. Fu, C. Schwarzer, T. Banzon, S. Jalickee, S. S. Miller, and T. E. Machen Flagellin-stimulated Cl- secretion and innate immune responses in airway epithelia: role for p38 Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L531 - L542. [Abstract] [Full Text] [PDF]

				C. S. Rogers, W. M. Abraham, K. A. Brogden, J. F. Engelhardt, J. T. Fisher, P. B. McCray Jr., G. McLennan, D. K. Meyerholz, E. Namati, L. S. Ostedgaard, et al. The porcine lung as a potential model for cystic fibrosis Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L240 - L263. [Abstract] [Full Text] [PDF]

				R. J. Lee, J. M. Harlow, M. P. Limberis, J. M. Wilson, and J. K. Foskett HCO3- Secretion by Murine Nasal Submucosal Gland Serous Acinar Cells during Ca2+-stimulated Fluid Secretion J. Gen. Physiol., July 1, 2008; 132(1): 161 - 183. [Abstract] [Full Text] [PDF]

				K. Hybiske, Z. Fu, C. Schwarzer, J. Tseng, J. Do, N. Huang, and T. E. Machen Effects of cystic fibrosis transmembrane conductance regulator and {Delta}F508CFTR on inflammatory response, ER stress, and Ca2+ of airway epithelia Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1250 - L1260. [Abstract] [Full Text] [PDF]

				R. J. Lee, M. P. Limberis, M. F. Hennessy, J. M. Wilson, and J. K. Foskett Optical imaging of Ca2+-evoked fluid secretion by murine nasal submucosal gland serous acinar cells J. Physiol., August 1, 2007; 582(3): 1099 - 1124. [Abstract] [Full Text] [PDF]

				C. H Goss and J. L Burns Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis Thorax, April 1, 2007; 62(4): 360 - 367. [Abstract] [Full Text] [PDF]

				H. R. de Jonge Cystic fibrosis mice rehabilitated for studies of airway gland dysfunction J. Physiol., April 1, 2007; 580(1): 7 - 8. [Full Text] [PDF]

				J. P. Ianowski, J. Y. Choi, J. J. Wine, and J. W. Hanrahan Mucus secretion by single tracheal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice J. Physiol., April 1, 2007; 580(1): 301 - 314. [Abstract] [Full Text] [PDF]

				J. V. Wu, M. E. Krouse, and J. J. Wine Acinar origin of CFTR-dependent airway submucosal gland fluid secretion Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L304 - L311. [Abstract] [Full Text] [PDF]

				M. M. Myerburg, M. B. Butterworth, E. E. McKenna, K. W. Peters, R. A. Frizzell, T. R. Kleyman, and J. M. Pilewski Airway Surface Liquid Volume Regulates ENaC by Altering the Serine Protease-Protease Inhibitor Balance: A MECHANISM FOR SODIUM HYPERABSORPTION IN CYSTIC FIBROSIS J. Biol. Chem., September 22, 2006; 281(38): 27942 - 27949. [Abstract] [Full Text] [PDF]

				S. T. Ballard, J. C. Parker, and C. R. Hamm Restoration of Mucociliary Transport in the Fluid-DepletedTrachea by Surface-Active Instillates Am. J. Respir. Cell Mol. Biol., April 1, 2006; 34(4): 500 - 504. [Abstract] [Full Text] [PDF]

				N. S. Joo, T. Irokawa, R. C. Robbins, and J. J. Wine Hyposecretion, Not Hyperabsorption, Is the Basic Defect of Cystic Fibrosis Airway Glands J. Biol. Chem., March 17, 2006; 281(11): 7392 - 7398. [Abstract] [Full Text] [PDF]

				J. J. Wine Acid in the airways. Focus on "Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis" Am J Physiol Cell Physiol, March 1, 2006; 290(3): C669 - C671. [Full Text] [PDF]

				S. T. Ballard, L. Trout, J. Garrison, and S. K. Inglis Ionic mechanism of forskolin-induced liquid secretion by porcine bronchi Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L97 - L104. [Abstract] [Full Text] [PDF]

				H. Liu, A. M. Mamoon, and J. M. Farley, Sr. Prostanoids Secreted by Alveolar Macrophages Enhance Ionic Currents in Swine Tracheal Submucosal Gland Cells J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 729 - 739. [Abstract] [Full Text] [PDF]

				R. Tarran, B. Button, M. Picher, A. M. Paradiso, C. M. Ribeiro, E. R. Lazarowski, L. Zhang, P. L. Collins, R. J. Pickles, J. J. Fredberg, et al. Normal and Cystic Fibrosis Airway Surface Liquid Homeostasis: THE EFFECTS OF PHASIC SHEAR STRESS AND VIRAL INFECTIONS J. Biol. Chem., October 21, 2005; 280(42): 35751 - 35759. [Abstract] [Full Text] [PDF]

				R. Robert, C. Norez, and F. Becq Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells J. Physiol., October 15, 2005; 568(2): 483 - 495. [Abstract] [Full Text] [PDF]

				R. Dajani, Y. Zhang, P. J. Taft, S. M. Travis, T. D. Starner, A. Olsen, J. Zabner, M. J. Welsh, and J. F. Engelhardt Lysozyme Secretion by Submucosal Glands Protects the Airway from Bacterial Infection Am. J. Respir. Cell Mol. Biol., June 1, 2005; 32(6): 548 - 552. [Abstract] [Full Text] [PDF]

				S. M. Rowe, S. Miller, and E. J. Sorscher Cystic Fibrosis N. Engl. J. Med., May 12, 2005; 352(19): 1992 - 2001. [Full Text] [PDF]

				S. M. Kreda, M. Mall, A. Mengos, L. Rochelle, J. Yankaskas, J. R. Riordan, and R. C. Boucher Characterization of Wild-Type and {Delta}F508 Cystic Fibrosis Transmembrane Regulator in Human Respiratory Epithelia Mol. Biol. Cell, May 1, 2005; 16(5): 2154 - 2167. [Abstract] [Full Text] [PDF]

				J. A. Best and P. M Quinton Salivary secretion assay for drug efficacy for cystic fibrosis in mice Exp Physiol, March 1, 2005; 90(2): 189 - 193. [Abstract] [Full Text] [PDF]

				M. E. Krouse, J. F. Talbott, M. M. Lee, N. S. Joo, and J. J. Wine Acid and base secretion in the Calu-3 model of human serous cells Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1274 - L1283. [Abstract] [Full Text] [PDF]

				T. Irokawa, M. E. Krouse, N. S. Joo, J. V. Wu, and J. J. Wine A "virtual gland" method for quantifying epithelial fluid secretion Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L784 - L793. [Abstract] [Full Text] [PDF]

				N. S. Joo, D. J. Lee, K. M. Winges, A. Rustagi, and J. J. Wine Regulation of Antiprotease and Antimicrobial Protein Secretion by Airway Submucosal Gland Serous Cells J. Biol. Chem., September 10, 2004; 279(37): 38854 - 38860. [Abstract] [Full Text] [PDF]

				K. Hentchel-Franks, D. Lozano, V. Eubanks-Tarn, B. Cobb, L. Fan, R. Oster, E. Sorscher, and J. P. Clancy Activation of Airway Cl- Secretion in Human Subjects by Adenosine Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 140 - 146. [Abstract] [Full Text] [PDF]

				S. T. Ballard and S. K. Inglis Liquid secretion properties of airway submucosal glands J. Physiol., April 1, 2004; 556(1): 1 - 10. [Abstract] [Full Text] [PDF]

				J. J. Wine and N. S. Joo Submucosal Glands and Airway Defense Proceedings of the ATS, January 1, 2004; 1(1): 47 - 53. [Abstract] [Full Text] [PDF]

				D. J. Thornton and J. K. Sheehan From Mucins to Mucus: Toward a More Coherent Understanding of This Essential Barrier Proceedings of the ATS, January 1, 2004; 1(1): 54 - 61. [Abstract] [Full Text] [PDF]

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				L. Trout, M. I Townsley, A. L Bowden, and S. T Ballard Disruptive effects of anion secretion inhibitors on airway mucus morphology in isolated perfused pig lung J. Physiol., June 15, 2003; 549(3): 845 - 853. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 277/52/50710    most recent M208826200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joo, N. S. Articles by Wine, J. J. Search for Related Content PubMed PubMed Citation Articles by Joo, N. S. Articles by Wine, J. J. Social Bookmarking                      What's this?